Androclus Therapeutics announced publication of Phase I/IIa clinical trial results of its AT-001 (dnaJP1) compound for treatment of rheumatoid arthritis (RA) in Proceedings of the National Academy of Sciences*. The product, developed at University of California, San Diego, demonstrated biological efficacy, with no significant side effects observed.
